Related references
Note: Only part of the references are listed.Effect of Intravenous 25OHD Supplementation on Bone Turnover and Inflammation in Prolonged Critically Ill Patients
Catherine Ingels et al.
HORMONE AND METABOLIC RESEARCH (2020)
Effect of 16-weeks vitamin D replacement on calcium-phosphate homeostasis in overweight and obese adults
Jakub Mesinovic et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors
Se Hyun Kim et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis
N. Charoenngam et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease
Stephen A. Strugnell et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
The Effect of Vitamin D Supplementation on Bone Metabolic Markers in Chronic Kidney Disease
Ashok Kumar Yadav et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study
Per-Anton Westerberg et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Biology of Fibroblast Growth Factor 23: From Physiology to Pathology
Marie Courbebaisse et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial
T. Kamelian et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Plasma FGF23 is not elevated in prostate cancer
Mariska C. Vlot et al.
CLINICA CHIMICA ACTA (2018)
Comparative Effects of Cholecalciferol and Calcitriol on Circulating Markers of CKD Mineral Bone Disorder A Randomized Clinical Trial
Leila R. Zelnick et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease
Ashok Kumar Yadav et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis
Amarnath Marthi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial
Belinda Spoto et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease
Christian Lerch et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
Armin Zittermann et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2018)
A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D3 Supplementation
Sophie De Niet et al.
NUTRIENTS (2018)
FGF23 Actions on Target Tissues-with and without Klotho
Beatrice Richter et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD
Vivek Kumar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels
C. Torino et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2017)
Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens
S. Minisola et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients
Claudia Torino et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
Cholecalciferol decreases inflammation and improves vitamin D regulatory enzymes in lymphocytes in the uremic environment: A randomized controlled pilot trial
Jose Tarcisio G. Carvalho et al.
PLOS ONE (2017)
Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial
Nayoung Han et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
Tumour-induced osteomalacia
Salvatore Minisola et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Effects of Single Vitamin D3 Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency
Dongdong Zhang et al.
ENDOCRINOLOGY AND METABOLISM (2017)
Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD
Adeera Levin et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Vitamin D3 supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: Results of an open label randomized clinical trial
Diana R. Mager et al.
CLINICAL NUTRITION (2017)
Effect of Calcitriol on FGF23 Level in Healthy Adults and its Dependence on Phosphate Level
Effrosyni Georgiadou et al.
IN VIVO (2017)
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease
Stuart M. Sprague et al.
AMERICAN JOURNAL OF NEPHROLOGY (2016)
Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study
Nao Souma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Plasma Desphospho-Uncarboxylated Matrix Gla Protein as a Marker of Kidney Damage and Cardiovascular Risk in Advanced Stage of Chronic Kidney Disease
Ilona Kurnatowska et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2016)
Update on FGF23 and Klotho signaling
Reinhold G. Erben
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients
C. Zoccali et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2016)
Nutritional Vitamin D Supplementation in Dialysis: A Randomized Trial
Ishir Bhan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism
Stuart M. Sprague et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Biochemical Parameters After Cholecalciferol Repletion in Hemodialysis: Results From the VitaDial Randomized Trial
Annick Massart et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate
Peter L. Havens et al.
ANTIVIRAL THERAPY (2014)
Decreased Conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 Following Cholecalciferol Therapy in Patients with CKD
Jason R. Stubbs et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population
Anna J. Jovanovich et al.
CLINICAL NEPHROLOGY (2014)
Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial
Carmine Zoccali et al.
HYPERTENSION (2014)
Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study
Thomas O. Carpenter et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Ovarian Cancer- Related Hypophosphatemic Osteomalacia-A Case Report
Hung-An Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Activation of FGF-23 Mediated Vitamin D Degradative Pathways by Cholecalciferol
Hala Alshayeb et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Soluble α-Klotho and Its Relation to Kidney Function and Fibroblast Growth Factor-23
Alexandra Scholze et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Plasma Fibroblast Growth Factor 23, Parathyroid Hormone, 25-Hydroxyvitamin D3, and Risk of Heart Failure: A Prospective, Case-Cohort Study
Romina di Giuseppe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Vitamin D Represses Dentin Matrix Protein 1 in Cementoblasts and Osteocytes
F. H. Nociti et al.
JOURNAL OF DENTAL RESEARCH (2014)
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study
Mario Cozzolino et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Impact of Vitamin D Supplementation on Arterial Vasomotion, Stiffness and Endothelial Biomarkers in Chronic Kidney Disease Patients
Nihil Chitalia et al.
PLOS ONE (2014)
Effects of High Doses of Cholecalciferol in Normal Subjects: A Randomized Double-Blinded, Placebo-Controlled Trial
Birgitte Nygaard et al.
PLOS ONE (2014)
The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study
Ditte Hansen et al.
BMC NEPHROLOGY (2014)
Hip Bone Loss Is Attenuated With 1000 IU but Not 400 IU Daily Vitamin D3: A 1-Year Double-Blind RCT in Postmenopausal Women
Helen M. Macdonald et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Oncogenic Osteomalacia due to FGF23-Expressing Colon Adenocarcinoma
David E. Leaf et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Effect of a 300 000-IU Loading Dose of Ergocalciferol (Vitamin D2) on Circulating 1,25(OH)2-Vitamin D and Fibroblast Growth Factor-23 (FGF-23) in Vitamin D Insufficiency
C. Turner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease
Ian H. de Boer et al.
KIDNEY INTERNATIONAL (2013)
Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism
Makoto Kuro-o
NATURE REVIEWS NEPHROLOGY (2013)
Influence of Cholecalciferol Supplementation in Hemodialysis Patients on Monocyte Subsets: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Eric Seibert et al.
NEPHRON CLINICAL PRACTICE (2013)
Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5
Eva Gravesen et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2013)
Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial
Thomas Larsen et al.
BMC NEPHROLOGY (2013)
High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial
Jessica A. Alvarez et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2012)
Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis
Laura Tripkovic et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2012)
Effect of Cholecalciferol Supplementation During Winter Months in Patients With Hypertension: A Randomized, Placebo-Controlled Trial
Thomas Larsen et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Cholecalciferol Supplementation in Chronic Kidney Disease: Restoration of Vitamin D Status and Impact on Parathyroid Hormone
Miriam G. Garcia-Lopes et al.
ANNALS OF NUTRITION AND METABOLISM (2012)
Accuracy of 6 Routine 25-Hydroxyvitamin D Assays: Influence of Vitamin D Binding Protein Concentration
Annemieke C. Heijboer et al.
CLINICAL CHEMISTRY (2012)
Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23
Sherri-Ann M. Burnett-Bowie et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Daily Variability in Mineral Metabolites in CKD and Effects of Dietary Calcium and Calcitriol
Tamara Isakova et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol
Ditte Hansen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D
Peter Marckmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
REGULATION AND FUNCTION OF THE FGF23/KLOTHO ENDOCRINE PATHWAYS
Aline Martin et al.
PHYSIOLOGICAL REVIEWS (2012)
Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase
Dagmar-Christiane Fischer et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2012)
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial
Ditte Hansen et al.
KIDNEY INTERNATIONAL (2011)
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism
Katherine Wesseling-Perry et al.
KIDNEY INTERNATIONAL (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Current status of clinical 25-hydroxyvitamin D measurement: An assessment of between-laboratory agreement
Neil Binkley et al.
CLINICA CHIMICA ACTA (2010)
Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD
James B. Wetmore et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Fibroblast growth factor 23 and its role in phosphate homeostasis
Isolde Ramon et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations
Erik A. Imel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Increased parathyroid expression of klotho in uremic rats
Jacob Hofman-Bang et al.
KIDNEY INTERNATIONAL (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents
V. Chel et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study
Danilo Fliser et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D
Shiguang Liu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Fibroblast growth factor-23 is regulated by lα,25-dihydroxyvitamin D
MT Collins et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells
M Ito et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo
H Saito et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism
H Nishi et al.
NEPHRON CLINICAL PRACTICE (2005)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Share Paper
